Triple-phase contrast-enhanced computed tomography findings in dogs with cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: Pilot study

犬胆管癌及肝细胞-胆管混合癌的三期增强CT检查结果:初步研究

阅读:2

Abstract

BACKGROUND: Recently, the usefulness of triple-phase contrast-enhanced computed tomography (CT) scans for liver tumors in canines has been reported. However, detailed information on the CT findings of cholangiocarcinoma (CCA) and combined hepatocellular-cholangiocarcinoma (cHCC-CCA) remains limited. AIM: This study aimed to retrospectively evaluate triple-phase contrast-enhanced CT findings in canine CCA and cHCC-CCA using objective parameters, such as CT values and morphological characteristics. METHODS: This study included eight dogs that underwent triple-phase contrast-enhanced CT scans and surgical removal and were pathologically diagnosed. Three CCA cases and five cHCC-CCA cases were analyzed. Parameters included CT values and mass sizes, CT values and lymph node sizes, and rim enhancement. "Rim enhancement" was defined as the contrast enhancement effect at the liver parenchyma-mass boundary. RESULTS: CT values for CCA were as follows: pre-contrast: 43.9 ± 3.6 Hounsfield units (HUs); arterial phase: 76.9 ± 22.5 HU; portal phase: 98.8 ± 37.7 HU; equilibrium phase: 90.9 ± 27.1 HU. For cHCC-CCA, the mean CT values were as follows: pre-contrast: 50.7 ± 6.1 HU; arterial phase: 80.2 ± 19.2 HU; portal phase: 95.0 ± 21.3 HU; equilibrium phase: 86.1 ± 13.4 HU. The peak contrast enhancement for both CCA and cHCC-CCA was in the portal phase. Rim enhancement appeared in the arterial phase in all CCA cases, whereas it appeared in the portal phase in 80% of cHCC-CCA cases, indicating a significant difference. CONCLUSION: Rim enhancement may help distinguish between CCA and cHCC-CCA. However, this study has a limited number of cases, and future large-scale, multicenter studies are warranted.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。